Latest Commercialisation News

TALi Digital (ASX:TD1) is raising up to $3.3 million through a Security Purchase Plan and Placement to fund its acquisition of Datasphere Analytics and advance its AI-driven education platform.

1414 Degrees has acquired full ownership of the Aurora Energy Precinct, consolidating control to drive development of renewable energy infrastructure and a 1 GW AI data centre project.

Provaris Energy has teamed up with Himile Heavy Industries to transition its hydrogen tank production from prototype to commercial scale, leveraging Himile's industrial manufacturing expertise and facilities in China.

Artrya has launched its AI-powered Salix® platform commercially in the US, securing three foundation health systems and raising $80 million to fuel growth. With FDA clearance for its Coronary Plaque module and a pivotal clinical study underway, the company is poised for scaling revenues amid a strong balance sheet.

Sparc Technologies has made its inaugural commercial delivery of ecosparc®, a graphene additive, to a major coatings manufacturer, underpinning its push to dominate the protective coatings market. The company also launched a discounted Share Purchase Plan to fuel ongoing commercial expansion.

Nanoveu's EMASS division has been granted a US patent for a silicon accelerator that dramatically speeds up AI object detection, underpinning its next-gen ECS-DoT chip now in production at TSMC.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Peppermint Innovation Limited posted a $2.4 million net loss for FY26 as it shifted from platform development to commercial execution in the Philippines, achieving key regulatory milestones and securing strategic investment.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

The Calmer Co. International Limited posted a record $8.1 million revenue for FY26, driven by retail and wholesale growth, yet recorded a $3.8 million net loss amid ongoing funding challenges and strategic investments.